Croda: Vaccine Adjuvants Business
Former Senior Executive at Brenntag
inpractise.com/articles/croda-vaccine-adjuvants-business
Croda: Vaccine Adjuvants Business(October 7, 2024)
Former Senior Executive at Brenntag
Interview Transcript
This is a snippet of the transcript, sign up to read more.
Why did you say that you sold the Biosector business to Croda?
The reason is that Brenntag is a distributor. We are not a manufacturing company. We don't want to compete with our principals or our customers. The majority of vaccine producers buy different products from franchises like GSK. They are our customers, and we cannot go into the market and compete with them. First, from a rational point of view. Second, regarding the manufacturing process, we are not manufacturers and do not want to be. We are distributors. We buy the finished product, stock it, and sell it.
This is a snippet of the transcript, sign up to read more.
Why is Croda so well-positioned in biotech?
The second point is in the UK market. I think the Minister of Health in the UK is providing some financial support for adjuvant development, specifically the next generation of adjuvant development. I can find the data on that. I don't have it with me now, but I can find the real data to support your research. Croda is not the number one player in the adjuvant market in terms of volume and value. However, they are positioned in the specialty adjuvant market, and they are developing significant knowledge in biotech.
This is a snippet of the transcript, sign up to read more.
Related Content
Croda: Life Sciences Specialty Chemicals
Former Senior Executive at Croda
IMCD: Principal - Distributor Dynamics
Former Managing Director at IMCD
IMCD Group: APAC Region, M&A Strategy & Management Changes
Former Vice President at IMCD Group
IMCD: Customer Value-Add
Former International Sales Manager at IMCD
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.